Colin Lee Novick Email & Phone Number

Tokyo, JP

Innovacell K.K. is a privately held, Clinical Stage regenerative medicine company focused on developing regenerative therapies that treat various forms of incontinence (both fecal and urinary). I provided the company's Austrian predecessor (Innovacell Biotechnologie AG) with many years of cell therapy regulatory consulting and advisory services before.

Salt Lake City, Utah, US

DiscGenics, Inc. is a privately held, Clinical Stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function to patients with degenerative diseases of the spine. I was selected by Dr. Yoshinori Shirono, founder of Ci:z Investment LLP, the lead Series C investor for DiscGenics, to represent his.

Adelaide, SA, AU

After assisting I'rom Group's acquisition of the CMAX business unit from IDT Australia, I was nominated and joined the resulting spin-out firm CMAX Clinical Research (Australia’s largest, longest running and most experienced, dedicated clinical trials unit) as a Director in DEC 2016

Shibuya-ku, Tokyo, JP

As a founding member (and current Managing Director), I have steered this company through 8 years of continued growth and specialization in the field of Japanese regenerative medicine (e.g. cell therapies, gene therapies, and tissue engineering). In terms of understanding of the Japanese regulations that surround this nascent industry and the trends that.

Founding Director of Regeneus Japan, a JV between Regeneus Ltd (ASX:RGS) and AGC Inc (TSE:5201).

Founded in 2000 Innovacell Biotechnologie AG is an Austrian biotech (a spin-off enterprise of the Innsbruck Medical University) that develops multiple cell therapies for incontinence. As one of the firm's 3 supervisory board members, I oversaw/appointed management board members and approved major business decisions. I was also actively involved in the.

Served as a Director for Binary.com's (currently re-branded as Deriv ) Japanese subsidiary, Binary K.K.. Among other things I assisted in the acquisition of a Type 1 Financial Instruments Business license from the Japanese regulators and assisted in the set up of operations for use post acquisition of said license.

New York, NY, US

10EQS is a next-gen ‘virtual workforce in a cloud’ that combines proven management consulting with on-line mass collaboration/crowd solving to address critical strategic business issues faced by top companies.10EQS allows clients to easily express complex business problems on-line and to receive high-quality solutions collaboratively solved by top experts.

Tokyo, Shibuya-ku, JP

In tandem with working as a Managing Director for CJ PARTNERS, I worked as a part of the ad-comm group company ad-med, to help said group further their services to clients in the healthcare and pharmaceutical industries.Services Include:- Business Strategy Development- Marketing Solutions- New Product Launch Strategy Development / Planning / Production.

JP

Provide M&A advisory services covering a broad range of industries, to Japanese firms looking to expand both within Japan and overseas.

Worldwide, OO

Market analysis on various sectors of the Japanese financial and pharmaceutical industries. Focused on various organizational compliance related projects within the financial services industry and R&D-related projects within the pharmaceutical industry.

Publication Assistant for IGES environmental journal IRES (International Review for Environmental Strategies); Translation of official documents and articles from Japanese to English and vice-versa; Research on the extent of worldwide CO2 emission levels; Taking the minutes in both English and Japanese at board-member meetings

Modeling for wetsuits and high-performance dry-suits